Rondo Therapeutics, Inc.

– Lilly is granted exclusive worldwide rights to develop a CD28-co-stimulatory therapeutic for a defined cancer target – Rondo Therapeutics receives upfront cash and is eligible to receive milestone payments and tiered royalties HAYWARD, CA, USA I December 04, 2024 I Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, today announced a research collaboration and license agreement with Eli Lilly and Company. This collaboration will combine Rondo Therapeutics’ proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulatory bispecific antibodies for solid tumor treatment. “By combining Rondo’s innovative approach to immune T cell engagers with Lilly’s deep knowledge and resources in oncology, we believe this partnership has the potential to significantly impact the treatment landscape for solid tumors,” said Shelley Force Aldred, CEO and co-founder of Rondo Therapeutics. “We are excited to collaborate with Lilly on our CD28 platform to advance the development of cancer therapies targeting solid tumors. Together, we are committed to accelerating the delivery of novel immuno-oncology therapies to the patients who need them most.” Under the terms of the agreement, Rondo Therapeutics will receive an undisclosed upfront cash payment and is eligible for additional development and commercial milestone payments, along with tiered royalties on commercial sales. Rondo Therapeutics’ proprietary platform features CD28-targeting binders with a wide range of co-stimulatory potencies designed to boost T cell-mediated tumor killing and overcome T cell exhaustion in the solid tumor microenvironment. Rondo’s platform delivers bispecific antibody therapeutics tailored to specific tumor targets, indications, and treatment regimens, offering a transformative alternative to traditional “one size fits all” strategies, unlocking the potential for durable responses in patients with solid tumors. About Rondo Therapeutics: Rondo Therapeutics is a biopharmaceutical company breaking new ground in cancer therapy. The company’s mission is to advance bispecific antibody therapies that address unmet needs in the treatment of solid tumors. Rondo is developing a new class of bispecific antibodies designed to harness the immune system to target and eliminate tumors with enhanced safety. Rondo Therapeutics is supported by Canaan Partners, Red Tree Venture Capital, Johnson & Johnson, SV Health Investors, and Novo Holdings. The company’s pipeline includes immune-engaging bispecifics for a range of solid tumors, including bladder and ovarian cancers. For more information, please visit www.rondotx.com. SOURCE: Rondo Therapeutics

Plus, news about Arrakis, Eli Lilly, Everest Medicines, Teva, Rondo Therapeutics, Trevi Therapeutics, Foresee Pharmaceuticals and Revolution Medicines: AstraZeneca taps new leader to run China business: The drugmaker named Iskra Reic as EVP of international, putting her in charge of its China business after Leon Wang was placed on leave while under investigation there. Wang was EVP of international and president of China. Reic, who launched the company’s vaccines and immune therapies unit, has been with AstraZeneca since 2001. — Jaimy Lee Janux’s $300M offering: The biotech is raising money after its stock soared on Tuesday thanks to early prostate cancer data . It’s been reported as a takeover target in the past. — Kyle LaHucik Arrakis shares first look at preclinical myotonic dystrophy type 1 data: Earlier this year, the RNA-targeted small molecule biotech helmed by industry veteran Michael Gilman shifted its focus from a lead cancer program to DM1, Endpoints News reported in March. “While there have been serendipitous discoveries of small molecule drugs that bind to RNA, we believe this is one of the clearest examples of a rationally designed small molecule that has been purpose-built to address an RNA disease target,” Gilman said in a Wednesday release. — Kyle LaHucik Lilly joins hot T cell engager space: The pharma giant, mostly in the news for its obesity medicines, has inked a cancer deal. It’s paying an undisclosed amount to California startup Rondo Therapeutics for a CD28-co-stimulatory bispecific antibody for an undisclosed cancer target. Multiple large pharmas have done T cell engager deals in recent months. — Kyle LaHucik Everest Medicines details early data for BTK inhibitor: In the ongoing Phase 1b/2a trial in China for patients with primary membranous nephropathy, 9 out of 11 (81.8%) patients taking the lowest dose achieved overall clinical remission after 36 weeks, and 10 out of 11 (91%) achieved immunological complete remission. In patients on the highest dose, 6 out of 7 (85.7%) patients achieved overall clinical remission. — Katherine Lewin Teva’s Ajovy bests placebo in pediatric migraine trial: Over 12 weeks, Ajovy “significantly” reduced monthly migraine days and monthly headache days compared to placebo in patients between six and 17 years old. The full data are set to be presented at the European Headache Congress in the Netherlands this week. — Katherine Lewin Trevi’s topline data for chronic cough drug: The human abuse potential study , which enrolled patients who are recreational drug users, showed a statistically significant lower “drug liking” for two doses of Trevi’s nalbuphine compared to butorphanol, a narcotic for pain with a high risk for addiction. But its stock $TRVI was down about 4% on Wednesday morning. — Katherine Lewin Foresee’s $42M raise: The Taipei and US biotech, which markets the prostate cancer drug Camcevi, secured the money by selling 18 million shares. — Kyle LaHucik Revolution Medicines upsized its public offering to $750 million, up from the $600 million it initially planned to raise . — Jaimy Lee

HAYWARD, Calif.--(BUSINESS WIRE)-- Rondo Therapeutics, a biopharmaceutical company pioneering next-generation bispecific antibodies, announces oral presentations at both Protein & Antibody Engineering Summit (PEGS) and Antibody Engineering & Therapeutics (AET) EU. Rondo Therapeutics will describe its immune-cell engaging bispecific antibody platforms and how it is building a clinical pipeline with a focus on treating solid tumors. The company will provide an update on its lead program, RNDO-564, a co-stimulatory T-cell engaging bispecific antibody targeting CD28 and Nectin-4 for the treatment of bladder cancer. “Presenting our data at PEGS and AET EU represents a significant milestone for our company. This is a golden age for bispecific antibodies and we are delighted to be driving innovation in the field. Targeted signaling through the CD28 pathway is showing a lot of promise as an effective strategy for overcoming the challenges presented by solid tumors. We look forward to sharing our unique approach and commitment to developing novel immunotherapy options for patients with solid tumors,” said Shelley Force Aldred, co-founder, and CEO of Rondo Therapeutics. Presentation Details Protein & Antibody Engineering Society (Boston, MA) Date: Wednesday, May 15 Title: Bispecific Antibody Combination Strategies for Treating Solid Tumors Presenter: Nathan D. Trinklein, PhD, Co-Founder and President, Rondo Therapeutics Conference Link: Antibody Engineering & Therapeutics EU (London, UK) Date: Tuesday, June 5 Title: Co-stimulatory Bispecific Antibody Strategies for Treating Solid Tumors Presenter: Starlynn Clarke, PhD, Director of Preclinical Biology, Rondo Therapeutics Conference Link: About Rondo Therapeutics Rondo Therapeutics is a biopharmaceutical company exploring new frontiers in cancer therapy. Rondo Therapeutics’ mission is to advance bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our solution is to create a new class of bispecific antibodies that harness the immune system’s power to target and eliminate tumors safely. For more information, please visit .